Media Coverage

Labcorp and Quest Diagnostics see solid growth on the horizon for laboratory companies as health systems try to blunt financial headwinds and patients seek more on-demand services. After acquiring lab assets from systems such as Minneapolis-based Allina Health, Columbus, Ohio-based OhioHealth, Franklin, Tennessee-based Community Health Systems and Fort Wayne, Indiana-based Parkview Health, the two dominant national commercial laboratory companies have set their focus on broadening test menus and direct-to-patient offerings.

Quest Diagnostics announced that Apple Health app users across most of the United States will be able to conveniently purchase a tailored Quest laboratory test panel that includes over 50 biomarkers directly through the app on iPhone and iPad later this year. The Quest laboratory panel is designed to deliver preventive health insights and includes biomarkers for assessing cardiometabolic health and organ function.

Medicare’s expansion of coverage for A1c for diabetes screening in 2024 was followed by significant increases in use of the test and detection of prediabetes, new data showed. The researchers compared laboratory data from Quest Diagnostics from January 1, 2022, to September 30, 2023, with data from the same period in 2024-2025. “This is the first study I’m aware of that specifically looks at how the testing patterns changed after Medicare adopted the rule,” said co-investigator Jason Ng, MD, clinical professor of medicine in the Division of Endocrinology and Metabolism at the University of Pittsburgh Medical Center in Pittsburgh.

Cardiologist Dr. Marc Penn joins Good Day DC. to discuss how new, advanced testing can reveal hidden cardiovascular risks that standard cholesterol panels often overlook.

Now, for the first time, you can test your biological age when you get your next round of blood work. Humanity Health Inc. and Quest Diagnostics are launching “Humanity Biological Age.” This test is available in the U.S. via questhealth.com. It’s a $29 add-on to certain existing Quest blood panels (like the Elite Health Profile or Men’s/Women’s Comprehensive Health Profiles) with no extra blood draw needed.

More than 860 North Carolinians have tested positive for Cyclospora this summer. They join thousands of Americans nationwide testing positive for the parasite at levels the country has never seen before. Two North Carolina cases have now been tied to a multistate outbreak involving shredded lettuce. A Cyclospora diagnosis requires a stool sample. In North Carolina, many of those samples during this summer’s historic rise in cases have been sent to Quest Diagnostics. “It’s been a busy summer, to say the least,” said Dr. Ann MacIntyre, senior medical director for infectious diseases at Quest Diagnostics.

Samples—and a certain stink—are accumulating at Quest Diagnostics thanks to the cyclosporiasis outbreak. On a laboratory table that normally sits empty, hundreds of feces samples are arranged in stacks six vials high. They’ve traveled by ground and plane, across seven different eastern U.S. states, for one purpose: to be tested for parasites, including cyclospora. And they’re coming faster than scientists here can test them. At Quest’s Clifton lab, workers are putting in extra hours.

Women with vaginosis are around three times as likely to also test positive for gonorrhea, chlamydia or other bacterial sexually transmitted infections, a new study says. The study results confirm guidance from the U.S. Centers for Disease Control and Prevention that women being treated for bacterial vaginosis should be tested for STIs, which can present with similar symptoms, researchers said in the journal O&G Open. "STIs can lead to serious reproductive and other health complications when left undetected and untreated,” senior researcher Dr. Damian Alagia said in a news release.

Quest Diagnostics president and CEO Jim Davis discusses how his company is implementing AI to help its patients on 'The Claman Countdown.'

As the liquid biopsy space has exploded in recent years, clinical laboratories are struggling to find sufficient staff to oversee and run these assays. "The problem is real," agreed Thomas Koch, senior VP and global head of research and development at Quest Diagnostics, adding that liquid biopsy "is a very fast-growing field with many players." Beyond the rise in demand for testing, test complexity has also contributed to the workforce shortage. Liquid biopsy tests often feature workflows involving dozens of steps along with sophisticated chemistries, hardware, software, and data analysis tools. "It's an entire ecosystem that is a little different from the standard clinical laboratory where you do, say, a calcium test, and then report it out," said Quest's Koch.

Quest Diagnostics on Thursday raised its full-year profit forecast, after demand for routine diagnostic testing helped the company beat second-quarter estimates. Shares of the New ‌Jersey-based company rose about 5% in premarket trading following the results. Demand for the company's diagnostic testing services was strong across its physician, hospital and consumer channels, Quest said. The results were "well above what ⁠was widely expected," Barclays analysts said.

Framing sexually transmitted infections (STIs) as a large-scale problem often obscured by percentages, Damian Alagia, III, MD, MS, MBA, FACS, Chief, Hospital and Health Systems, and Senior Medical Director, Advanced Diagnostics / Women's Health, Quest Diagnostics, argued that universal, non-judgmental testing is central to reaching reproductive-age women. Alagia said absolute figures convey the scale more effectively than rates, noting over 1.5 million patients annually with chlamydial infections, some 190,000 patients with syphilis, and nearly 4,000 babies with congenital syphilis, in 2024 data from the Centers for Disease Control and Prevention (CDC).

Nearly one in five American workers tested positive for drug use in long-term screenings last year, driven by a rise in cannabis consumption that is forcing companies to reevaluate their hiring practices. According to new data from Quest Diagnostics, 19.1 percent of workers screened via hair analysis in 2025 returned a positive result, representing a 46 percent increase from 2021. Marijuana accounted for 52.5 percent of those positive hair tests.

Quest is the largest reference laboratory to embed oncology molecular ordering into OncoEMR MPI, with projected reach to 4,700 clinicians across ~1,600 community oncology sites. Integration targets administrative friction from multi-biomarker orders and dense reports by reducing ordering steps, accelerating account setup, and returning more usable results inside routine EHR workflows.

The Quest Diagnostics Foundation said this week that it has awarded nearly $5 million in grant funding to four Miami-area non-profits to improve chronic and maternal health outcomes. With the funding, which was granted to the Florida International University Foundation, Urban Health Partnerships, The Health Council of South, and US Hunger, the Quest Diagnostics Foundation aims to expand healthcare access in the area, including through no-cost lab testing.

Quest Diagnostics said Wednesday that its Haystack MRD test has received approval from the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP) for use in identifying residual or recurring disease in patients with a range of solid tumors. With the approval, Haystack MRD is now available for patient testing in all 50 states and the District of Columbia. Quest launched the circulating tumor DNA liquid biopsy test in late 2024.

A hard-to-kill species of pneumonia-causing bacteria that has traditionally been found mainly in hospitals is now spreading in U.S. community settings, according to research that could help lead to new treatments. To learn more about its patterns of spread, researchers analyzed multidrug-resistant Klebsiella pneumoniae detected in urine and blood samples from more than 2,000 people in 42 states at local offices ⁠of Quest Diagnostics, a leading provider of outpatient laboratory testing.

Over the past year, Alzheimer’s blood testing has moved from research into clinical practice. Since May 2025, the field has seen its first US Food and Drug Administration (FDA)-cleared blood test and its first clinical practice guideline for blood-based biomarkers. Blood testing may also reduce the number of patients referred for amyloid PET imaging. Michael Racke, MD, medical director of neurology at Quest Diagnostics, points to research he co-authored suggesting that a blood test measuring amyloid beta 42 and 40 proteins (Aβ42/40) could reduce PET scan evaluations by about 40% by helping rule out Alzheimer’s disease as the cause of mild cognitive impairment. “Ruling out Alzheimer’s disease can prompt investigation of non-Alzheimer’s disease causes of mild cognitive impairment or dementia. When patients receive the right care at the right time, unnecessary costs may be reduced,” Racke says.

Chronic medical issues are frustrating for both doctors and patients, who just want to feel better. Tammie Robie, 51, struggled for nearly 20 years with blood pressure that was resistant against multiple medications. She pushed through her days as a wife, mother, teacher and competitive runner. Dr. Sanjay Dixit, the medical director for Quest Diagnostics, said PA was considered uncommon for many years. “Primary aldosteronism occurs when the adrenal glands produce too much aldosterone, a hormone that helps regulate sodium and potassium in the blood,” he said. The adrenal glands are located on top of the kidneys. According to Dixit, the Endocrine Society recommended in 2025 that all patients with hypertension be evaluated for PA. He notes that nearly half of all adults, or nearly 120 million people, have high blood pressure.

Postpartum body odor and sweating are common and generally not a cause for concern. Hormonal changes, milk production, and excess fluid shedding contribute to postpartum body odor. Damian Pat Alagia III, MD, MS, MBA, medical director for women’s health at Quest Diagnostics, explains that a pregnant person gains up to 10 pounds of amniotic fluid, blood, and other fluids.“Once the baby is born, the fluid needs somewhere to go," Dr. Alagia adds. Because of this, postpartum parents often experience increased sweating. "This is the body’s way of flushing out these excess fluids.”

Primary aldosteronism (PA) is a serious condition that affects as many as 5 to 10 percent of adults with high blood pressure (BP). High BP is widely prevalent in the U.S., nearly half of all adults (almost 120 million individuals) have it. Yet, for many years, PA was considered uncommon. However, recent research shows PA is both prevalent and under-detected. Untreated, it significantly raises risk of heart attack, stroke, and kidney disease.

Alzheimer’s disease (AD) is the major cause of dementia worldwide that leads to morbidity, long term care utilization, and significant healthcare costs. Dr. Yonghong Li and his colleagues at Quest Diagnostics performed a study to determine the efficacy and cost-effectiveness of using blood-based biomarker as a triage in Alzheimer’s disease testing. Dr. Michael K. Racke, Medical Director of Neurology at Quest Diagnostics and a co-investigator of this study summarized their findings.

Early cancer detection once meant imaging, pathology, and a defined set of screening tests with established follow-up pathways. Today, circulating tumor DNA assays, minimal residual disease (MRD) testing, and multi-cancer early detection platforms are expanding what is possible, often faster than the health systems meant to operationalize them.Yuri Fesko, MD, Senior Vice President and Chief Medical Officer for Quest Diagnostics, sees both extraordinary promise and practical disconnect.

In this episode of the WHOOP Podcast, WHOOP Founder and CEO Will Ahmed sits down with Quest Diagnostics CEO Jim Davis to discuss the partnership behind WHOOP Advanced Labs. Will and Jim discuss how combining blood biomarkers with continuous physiological data is reshaping consumer health.

City of Hope is implementing the Haystack minimal residual disease (MRD) test from Quest Diagnostics for clinical trial participants with solid tumor cancers. The research aims to guide disease management for patients with breast, colorectal, ovarian, and prostate cancer.

Quest Diagnostics on Tuesday raised its forecast for 2026 profit and revenue after posting first-quarter results above Wall Street estimates, citing resilient demand for routine diagnostic testing. Shares of the ​New Jersey-based company were up about 4% in early trading.

A blood test based from a South Baltimore lab is making treatment clearer for cancer patients. HaystackMRD, made by Haystack Oncology within Quest Diagnostics, looks for signs of cancer that conventional methods may miss. While it's been in development for many, many years, the test was made clinically available for oncologists and pharmaceutical partners in late 2024.

In this exclusive interview, Quest Diagnostics’ Ines Dahne-Steuber discusses their daytime kidney care lab strategy with MLO Editor in Chief, Christina Wichmann.

Per- and polyfluorinated alkyl substances, or PFAS, are known by many as “forever chemicals” due to the way they can accumulate and linger in the environment and body. These chemicals are widely used in thousands of industrial and consumer products and may enter the body through contaminated food and water. Research by Quest Diagnostics outlined similar results: men that were tested using the company’s PFAS blood test had higher PFAS concentrations in their blood than women who were tested.

Helio Genomics and Quest Diagnostics have partnered to expand access to a blood-based liver cancer test across the U.S. Starting in April, providers with a Quest account will be able to order HelioLiver, a test designed for early detection of hepatocellular carcinoma, through Quest’s network, according to a March 18 news release shared with Becker’s.

Guardant Health’s Shield blood-based colorectal cancer screening test is now available for physician ordering through Quest Diagnostics’ nationwide network, the companies announced March 10, giving clinicians a new avenue to access the only blood test with full Food and Drug Administration approval as a primary colorectal cancer (CRC) screening option for average-risk adults aged 45 and older.

Several large healthcare organizations have announced they have signed on to Google Cloud for Gemini-powered AI agents for patient engagement, improved workflows, revenue cycle capabilities and easier-to-read lab results. At HIMSS26, Google Cloud will show how agentic AI can lead healthcare organizations from siloed data entry to automated results. Quest Diagnostics, which offers diagnostic information services, has announced Quest AI Companion, a new AI-powered chat feature that helps individuals understand Quest laboratory test results. Through the app and portal MyQuest, individuals can ask questions about their test results and receive explanations in a HIPAA-compliant solution.

Quest Diagnostics is launching a chatbot tailored for laboratory test results as it seeks to allow patients the ability to come to terms with their findings and perform deeper dives on their own health. The Quest AI Companion can probe data from patients’ labs for up to five years in order “to help explain results and uncover potential health risks,” according to a March 2 statement.

Quest Diagnostics, a leading provider of diagnostic information services with headquarters in Secaucus, announced that Benjamin Beauvalot has joined the company as senior vice president, chief strategy and M&A officer. “Ben has an extensive track record of delivering successful growth, M&A and transformation strategies for world-class health care organizations,” Davis said.

Quest Diagnostics said its Flow Cytometry MRD for Myeloma test detects minimal residual disease (MRD), the small number of cancer cells that can remain in the body after treatment and potentially lead to relapse, “at a fraction of the cost” of other methods. “Our Flow Cytometry MRD for Myeloma test harnesses cutting-edge science and technology to deliver ultrasensitive insights from a noninvasive blood test, thereby improving care and value for patients and the healthcare system,” Yuri Fesko, MD, Quest’s senior vice president and chief medical officer, said in a company press release.

In 2020, as many as 5.8 million Americans were living with Alzheimer’s Disease (AD)—a number projected to nearly triple to 14 million people by 2060.1 As changes in the brain can begin years before the first symptoms appear, the science around assessing risk and diagnosing AD and other dementias is complex and continues to evolve with the publication of new research. (By Michael K. Racke, MD)

Quest Diagnostics reported Tuesday a 7 percent year-over-year increase in its Q4 2025 revenue. Revenue for the three months ended Dec. 31, 2025, was $2.81 billion, up from $2.62 billion in the same quarter last year and above the consensus Wall Street estimate of $2.76 billion. Requisition volumes rose 9 percent during the quarter while revenue per requisition fell less than 1 percent. Organic requisition volume rose 8 percent year over year, the Secaucus, New Jersey-based company said.

Forever chemicals. They’re everywhere — from non-stick pans to seafood to cosmetics. 25 Investigates worked with Quest Diagnostics, which offers a PFAS blood panel that screens for nine common forever chemicals for $350. Quest allowed us to film most of my blood test. We went in before the lab opened one January morning to protect patient privacy. Kavanaugh found the test itself to be quick and painless — just one vial of blood. Quest says it began offering the PFAS blood test in 2024. Quest says theirs is the first PFAS blood test available as a consumer-initiated test with physician oversight based on recommendations by the National Academies of Sciences, Engineering, and Medicine (NASEM).

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations.

Quest Diagnostics CMO Dr. Yuri Fesko joins Value Health Voices to decode the Clinical Laboratory Fee Schedule, the impact of PAMA and SALSA, and the future of precision medicine.

As Quest Diagnostics President and CEO Jim Davis noted at the 44th Annual JP Morgan Healthcare Conference last week, the RESULTS Act still needed to go through markup in a House subcommittee, then receive consideration in the Senate, undergo a technical feasibility assessment by the US Centers for Medicare and Medicaid Services, and then receive a score from the Congressional Budget Office. "That's a lot of work to be done in 18 days," he said. Davis added, however, that he is "optimistic that the RESULTS Act will get passed in 2026" and that Congress will pass a temporary delay as long as the RESULTS Act is making progress toward passage.

Quest and Labcorp may be archrivals in the diagnostic testing market, but they appear to agree on at least one thing: the potential demand for quick, at-home testing for women’s sexual health. The lab giants, in separate agreements announced Thursday, Jan. 8, have added Visby Medical’s newly approved, fully at-home PCR test for sexually transmitted infections to their lineup of direct-to-consumer women’s health offerings.

Southfield, Mich.-based Corewell Health and Secaucus, N.J.-based Quest Diagnostics have finalized a lab joint venture and hospital lab management agreement. Quest Diagnostics and Corewell Health’s existing labs will continue to provide services to the joint venture until a 100,000-square-foot centralized lab at the Corewell Health Southfield Center opens in the first quarter of 2027. The new facility will feature advanced diagnostic technologies, including high-throughput molecular testing and automated microbiology.

Quest Diagnostics handles the blood and other biological specimens of one in three Americans every year — and much of the testing, processing and logistics of those samples runs largely unseen through Tampa Bay.

AI, new diagnostics, and shifting care delivery models are among the clinical laboratory predictions for 2026. Cardiometabolic testing is one example, where labs are being asked to look beyond single endpoints. “In 2025, we saw many individuals focus on weight loss as a means of potentially improving their cardiometabolic health,” says Mouris Saghir, PhD, vice president and general manager for cardiometabolic, endocrine, and wellness at Quest Diagnostics.

Lab testing companies including giants Quest Diagnostics and LabCorp are pressing Congress to stop hundreds of millions of dollars of Medicare cuts for diagnostic tests that are due to take effect at the end of January. Their push could add to the health care issues piling up on lawmakers' plates as the calendar flips over. Clinical lab companies say letting the cuts take effect will leave them with less money to spend on creating new diagnostics or technologies to generate quicker results. "Labs play a critical part in trying to keep the nation well — identifying that risk before it ever even happens," said Yuri Fesko, chief medical officer at Quest.

Quest Diagnostics, a cancer treatment laboratory located in Lewisville, was honored by the Lewisville City Council after developing a medical breakthrough that could decrease the risk of diseases returning to treated patients. The laboratory was recognized for its achievement in developing Haystack MRD, a non-invasive, tumor-informed MRD test that searches for tiny tumor fragments in people who have previously or currently have a solid tumor.

In our latest podcast, Elizabeth Marlowe, PhD, D(ABMM), discusses the findings of Quest Diagnostics' large US HIV testing study, which showed a significant decline in HIV drug resistance across major antiretroviral classes, reflecting the impact of modern high-barrier therapies and improved viral suppression.

Even though exercise is good for us, working out can sometimes feel stressful: fitting in time for the gym, making sure we have clean workout clothes, monitoring our daily step count, pushing our runs, rides, and reps to be faster, harder, and just, well, more. If this sounds familiar, you’ll be pleased (and surprised!) to know that the latest fitness trend is all about doing less. If this sounds familiar, you’ll be pleased (and surprised!) to know that the latest fitness trend is all about doing less. In fact, it’s not a traditional workout at all—but it does have some legit benefits for physical health and mental wellbeing. “Getting up and moving around is good for your mental health,” says Marc Penn, M.D., Ph.D., FACC, a senior advisor and medical director of cardio-metabolic endocrine at Quest Diagnostics. Low-intensity activity can improve mood. Plus, clutter can add to stress and mental health issues, so if you’re using your Zone Zero time to tidy up, you get a two-for-one.